A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Cathelijne H. van der Wouden et al.|The Lancet|2023Cited by 508
Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are AvailableMatthias Samwald, Richard D. Boyce, Daniel C. Malone et al.|PLoS ONE|2016Cited by 81